Skip to main content

Table 3 Association between circulating CD45neg subpopulations and clinicopathological features of MBC patients

From: In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis

   Absolute number Fraction over CD45neg (%)
   E CTC EM CTC ETOT CTC MES NEG CD45neg EM CTC ETOT CTC MES NEG
Tumor characteristics
 HER2 Positive
(N = 11)
3
(0; 9)
0
(0; 3)
3
(1; 12)
22
(6; 42)
0
(0; 14)
42
(19; 118)
0
(0; 3)
16
(4; 25)
81
(33; 97)
0
(0; 38)
  Negative
(N = 36)
8
(4; 27)
4
(0; 13)
15
(5; 35)
80
(15; 124)
4
(0; 13)
102
(60; 153)
4
(0; 14)
17
(6; 39)
74
(40; 88)
4
(0; 15)
  p* 0.12 0.029 0.037 0.022 0.84 0.046 0.035 0.37 0.70 0.94
 Profile Luminal
(N = 25)
8
(4; 32)
4
(1; 15)
16
(6; 53)
72
(14; 103)
0
(0; 9)
97
(59; 197)
4
(0; 14)
19
(6; 55)
70
(39; 90)
0
(0; 6)
  HER2-positive
(N = 11)
3
(0; 9)
0
(0; 3)
3
(1; 12)
22
(6; 42)
0
(0; 14)
42
(19; 118)
0
(0; 3)
16
(4; 25)
81
(33; 96)
0
(0; 38)
  TNBC
(N = 11)
9
(2; 24)
3
(0; 9)
15
(2; 30)
84
(29; 125)
9
(5; 18)
124
(60; 150)
2
(0; 8)
16
(3; 21)
79
(60; 86)
15
(4; 16)
  p** 0.30 0.044 0.087 0.052 0.092 0.12 0.064 0.35 0.93 0.056
 Ki-67 <14 %
(N = 10)
7
(4; 35)
7
(0; 18)
18
(6; 53)
42
(6; 103)
0
(0; 4)
76
(41; 197)
4
(0; 31)
19
(8; 63)
63
(37; 90)
0
(0; 5)
  ≥14 %
(N = 34)
8
(2; 16)
2
(0; 6)
10
(3; 30)
55
(20; 92)
8
(0; 18)
99
(42; 138)
2
(0; 7)
16
(5; 25)
77
(41; 86)
8
(0; 16)
  p* 0.45 0.15 0.37 0.64 0.039 0.74 0.33 0.39 0.90 0.087
Metastatic site
 Bone Yes
(N = 29)
10
(4; 32)
4
(0; 15)
20
(7; 52)
45
(14; 84)
2
(0; 12)
95
(48; 126)
5
(0; 14)
25
(14; 55)
60
(33; 81)
2
(0; 14)
  No
(N = 29)
4
(1; 6)
0
(0; 4)
5
(1; 12)
55
(20; 129)
6
(0; 18)
89
(23; 150)
0
(0; 2)
7
(3; 16
85
(75; 90)
6
(0; 16)
p* 0.0072 0.024 0.0058 0.34 0.43 0.97 0.0096 0.0006 0.012 0.48
 Liver Yes
(N = 22)
9
(4; 27)
3
(0; 9)
15
(4; 45)
42
(15; 75)
6
(0; 14)
90
(41; 126)
3
(0; 14)
25
(10; 55)
63
(33; 84)
4
(0; 15)
  No
(N = 25)
6
(1; 10)
3
(0; 9)
10
(2; 21)
84
(20; 123)
3
(0; 12)
103
(42; 156)
2
(0; 6)
9
(3; 19)
81
(58; 89)
2
(0; 15)
  p* 0.28 0.99 0.27 0.28 0.87 0.47 0.48 0.011 0.067 0.86
 Lung Yes
(N = 16)
9
(4; 20)
1
(0; 6)
10
(6; 30)
57
(23; 126)
6
(0; 13)
87
(42; 153)
3
(0; 14)
12
(4; 30)
79
(49; 87)
5
(0; 16)
No
(N = 31)
6
(2; 27)
3
(0; 15)
10
(3; 45)
45
(10; 92)
3
(0; 14)
95
(23; 135)
0
(0; 6)
17
(6; 33)
75
(33; 89)
2
(0; 15)
p* 0.69 0.23 0.86 0.26 0.71 0.72 0.16 0.36 0.50 0.74
 CNS Yes
(N = 3)
24
(8; 47)
6
(0; 21)
45
(8; 53)
45
(30; 75)
43
(14; 90)
126
(97; 180)
6
(0; 12)
25
(6; 55)
31
(25; 60)
34
(14; 50)
No
(N = 44)
6
(2; 20)
3
(0; 9)
10
(3; 32)
53
(15; 100)
3
(0; 12)
85
(37; 143)
2
(0; 10)
16
(5; 32)
79
(40; 89)
2
(0; 15)
p* 0.16 0.56 0.26 1.0000 0.016 0.26 0.75 0.51 0.082 0.020
 Number of sites 1
(N = 16)
5
(2; 9)
1
(0; 10)
7
(2; 17)
55
(13; 93)
1
(0; 9)
82
(41; 122)
2
(0; 9)
9
(3; 21)
82
(47; 91)
1
(0; 14)
≥ 2
(N = 31)
9
(3; 27)
3
(0; 9)
15
(4; 36)
45
(15; 123)
5
(0; 14)
97
(41; 156)
2
(0; 12)
19
(6; 36)
70
(37; 86)
5
(0; 16)
p* 0.22 0.76 0.19 0.84 0.40 0.67 0.78 0.16 0.28 0.61
  1. Results are expressed as median (25th, 75th percentile). Bold cells indicate significant (p <0.05) differences as detected by Wilcoxon rank-sum test (*) or Kruskal-Wallis test (**), as appropriate
  2. E CTC subset of CD45neg expressing epithelial markers only, EM CTC subset of CD45neg coexpressing mesenchymal and epithelial markers, ETOT CTC CD45neg cells expressing epithelial markers independently from the expression of mesenchymal markers, MBC metastatic breast cancer, MES subset of CD45neg expressing mesenchymal markers only, NEG subset of CD45neg negative to the antibody cocktail, CNS central nervous system, HER2 human epidermal growth factor receptor 2